AKT1 and breast cancer: Mild α-TOS treatment (10 μM) and a low concentration of PS (5 or 10 μM) largely inhibited AKT (Figure 4B) and ERK (Figure 4C) activation, suggesting that α-TOS and PS exposure in combination resulted in a highly effective synergistic disruption of breast cancer cell proliferation.